Basco L K, Le Bras J
Centre National de Référence pour la Chimiosensibilité du Paludisme, Hôpital Bichat-Claude Bernard, Paris, France.
J Eukaryot Microbiol. 1994 May-Jun;41(3):179-83. doi: 10.1111/j.1550-7408.1994.tb01493.x.
The mitochondrion appears to be essential for the growth of asexual, intraerythrocytic stages of Plasmodium falciparum and may thus be a suitable chemotherapeutic target. The in vitro activity of almitrine, a mitochondrial ATP synthetase inhibitor used for the treatment of hypoxemia, was compared with other mitochondrial inhibitors against chloroquine-susceptible and chloroquine-resistant P. falciparum using an isotopic semimicro drug susceptibility assay. The 50% inhibitory concentration (IC50) values of almitrine (range: 2.6-19.8 microM) were within similar range of values of other mitochondrial ATP synthetase inhibitors and doxycycline, a mitochondrial protein synthesis inhibitor. Almitrine was equally active against chloroquine-susceptible and chloroquine-resistant parasites. Drug combination studies showed no interaction between chloroquine and almitrine. Our results suggest that almitrine, a clinically safe drug, may represent a lead compound with a specific target against the mitochondrial ATP synthetase which may be useful for antimalarial chemotherapy.
线粒体似乎对恶性疟原虫无性、红细胞内期的生长至关重要,因此可能是一个合适的化疗靶点。使用同位素半微量药物敏感性试验,将用于治疗低氧血症的线粒体ATP合成酶抑制剂氨苯蝶啶的体外活性与其他线粒体抑制剂针对氯喹敏感和氯喹耐药的恶性疟原虫进行了比较。氨苯蝶啶的50%抑制浓度(IC50)值(范围:2.6 - 19.8微摩尔)与其他线粒体ATP合成酶抑制剂以及线粒体蛋白质合成抑制剂强力霉素的值在相似范围内。氨苯蝶啶对氯喹敏感和氯喹耐药的寄生虫同样具有活性。药物联合研究表明氯喹和氨苯蝶啶之间没有相互作用。我们的结果表明,氨苯蝶啶作为一种临床安全的药物,可能代表一种针对线粒体ATP合成酶的具有特定靶点的先导化合物,这可能对抗疟化疗有用。